Wall Street Increases Loss Estimates for Exact Sciences Following Details of Clinical Trial Plans | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – One day after Exact Sciences announced its second-quarter earnings and provided details about the clinical trial for its colorectal cancer screening test, Wall Street reacted in mixed fashion, as several analysts increased their loss-per-share estimates for 2011 and 2012, and one downgraded Exact Sciences' stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.